Other languages BioCardia, Inc.

Equities

BCDA

US09060U5074

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
0.3766 ^USD	+2.34%		+4.61%	-43.30%

25/04	BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort	CI
27/03	Transcript : BioCardia, Inc., 2023 Earnings Call, Mar 27, 2024

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort	25/04
BioCardia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
BioCardia, Inc. and StemCardia, Inc. Announce Long-Term Partnership to Advance StemCardia?s Investigational Pluripotent Stem Cell Product Candidate for Treatment of Heart Failure	13/03
BioCardiaAnnounces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study	12/03
Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure	04/03
BioCardia, Inc. Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA	08/02
BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction	19/12
BioCardia, Inc. Announces Expected Cardiamp Heart Failure Japan Approval Based on Pharmaceutical and Medical Device Agency Consultation Minutes	18/12
BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure	29/11
Sector Update: Health Care Stocks Slightly Advancing Late Afternoon	17/11
Sector Update: Health Care	17/11
BioCardia to Sell $1.3 Million Shares to Healthcare Investor; Shares Fall	17/11
Sector Update: Health Care Stocks Higher Late Afternoon	15/11
Top Midday Gainers	15/11
Sector Update: Health Care Stocks Advancing in Afternoon Trading	15/11
Sector Update: Health Care	15/11
BioCardia Climbs Amid FDA Approval for Phase 3 Trial of CardiAMP Cell Therapy for Ischemic Heart Failure	14/11
BioCardia, Inc. Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure	14/11
BioCardia, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
BioCardia Files $50 Million Mixed Shelf; Shares Rise	20/23/20

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages BioCardia, Inc.

Equities

BCDA

US09060U5074

Other languages

Filters